Forskolin is a plant compound that directly switches on a key cell signal reaching many body systems. Its most consistent human effect is lowering pressure inside the eye, mainly as eye drops alongside standard glaucoma care. Evidence for fat loss from capsules is thin and mixed. Safety in short use appears reasonable; overall promise remains unproven and inexpensive. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood pressure | ~110–125 / 70–80 mmHg | Detects additive blood-pressure lowering |
| Resting heart rate | 55–70 bpm | Flags heart-rate increase |
| Fasting insulin | 2–6 µIU/mL | Tracks the possible metabolic benefit |
| Fasting glucose | 75–90 mg/dL | Context for insulin and metabolic response |
| HDL cholesterol | >55 mg/dL (men), >65 mg/dL (women) | One marker improved in a forskolin trial |
| Body composition (body-fat %) | Men 10–20%, Women 18–28% | Primary outcome for the fat-loss rationale |
| Intraocular pressure | 10–21 mmHg | Relevant only for glaucoma-directed use |
Cadence: Blood pressure and pulse at baseline, 1–2 weeks, and 4 weeks; metabolic and body-composition markers reassessed at the end of an 8–12 week block.